| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Theriva Biologics, Inc. (TOVX) has 4 insiders with recent SEC Form 4 filings, including 9 buys and 0 sells. TOVX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 475.0K | $154.8K | - | |
| Dir | 75.0K | $24.4K | - | |
| Dir | 75.0K | $24.4K | - | |
| Dir | 75.0K | $24.4K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 7, 2023 | Shallcross Steven A | CEO And CFO | Buy | 14,000 | $0.69 | $9,703.40 | +5.9% | -26.7% | -61.9% | |
| Jun 6, 2023 | Shallcross Steven A | CEO And CFO | Buy | 26,000 | $0.63 | $16,452.80 | +12.4% | -19.6% | -56.4% | |
| Feb 10, 2023 | Shallcross Steven A | CEO And CFO | Buy | 25,000 | $1.04 | $26,075.00 | +13.5% | -33.8% | -49.5% | |
| Feb 2, 2023 | Shallcross Steven A | CEO And CFO | Buy | 25,000 | $0.94 | $23,512.50 | +15.6% | -31.9% | -45.7% | |
| Jan 25, 2023 | Shallcross Steven A | CEO And CFO | Buy | 25,000 | $0.87 | $21,825.00 | +18.5% | -19.3% | -50.9% | |
| Jan 20, 2023 | Shallcross Steven A | CEO And CFO | Buy | 25,000 | $0.75 | $18,705.00 | +22.7% | -7.1% | -45.7% | |
| Dec 29, 2022 | Shallcross Steven A | CEO And CFO | Buy | 100,000 | $0.44 | $43,700.00 | +1,000% | +47.8% | -6.5% | |
| May 10, 2021 | Shallcross Steven A | CEO And CFO | Buy | 50,000 | $0.49 | $24,595.00 | +100.0% | +7.2% | -51.0% | |
| Aug 23, 2019 | Shallcross Steven A | CEO And CFO | Buy | 50,000 | $0.42 | $20,785.00 | New | - | - |